Patient Groups such as HepCBC provide patient input to the Canadian Agency for Drugs and Technologies in Health (CADTH) and the Canadian Drug Review (CDR) which helps them determine whether they should approve drugs for use in Canada, and what restrictions and criteria should be applied to their use. Here are some new (SHORT but GREAT!) YouTube videos which show why this input is so critical, and how it is used to benefits patients such as US! CLICK HERE
Gilead signs hepatitis C drug (sofosbuvir - SOVALDI and ledipasvir) pact to make treatment available in low income countries (Reuters, Sept. 15, 2014) "U.S. drugmaker Gilead Sciences Inc GILD.O has licensed its hepatitis C drug Sovaldi to seven India-based drugmakers that will sell far cheaper versions of the $1,000-a-pill medicine in 91 developing nations...Gilead said it would also launch its own branded Sovaldi in India at a price of $300 a month. The...
On Sept. 8, 2014, Dr. Paul Marotta of London Health Sciences Centre, presented "Transformation of HCV Management: The IFN-free Era". To access a PDF of this highly-informative and "up-to-the-minute" presentation, click HERE: DrPaulMarotta_20140908_HCV_Treatment_Presentation. Many thanks, Dr. Marotta, for generously sharing these excellent materials with HepCBC's online members.
Pauline Londeix’s presentation at the International AIDS conference on HCV pricing and "the future of HCV and HIV treatments" Thursday 24 July 2014 Pauline Londeix, leader of the Hepatitis C Act Up Campaign in Bangkok in February (http://actupbasel.org/actupbasel/?Pharma-refuses-to-ensure-access-to) made an important speech today in Australia at the International AIDS Conference. Drug pricing policy is a very controversial topic internationally, particu
Read the unanimous UN/WHO resolution in full here: http://apps.who.int/gb/ebwha/pdf_files/EB134/B134_R18-en.pdf From IP-Watch article: "The resolution asks states to consider using the flexibilities endorsed in the World Trade Organization Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) to promote access to specific pharmaceutical products. The director general is also asked to provide necessary technical support to countries, in
On October 1, 2013 the Canadian Agency for Drugs and Technologies in Health (CADTH) released a call for patient input into Gilead Science's new HCV drug, SOFOSBUVIR. In order to prepare our Patient Group submission by CADTH's October 23rd (noon, PST) deadline, HepCBC is ASKING for INPUT from HCV+ people and caregivers from throughout Canada, by Sunday, October 20th (midnight, PST). CLICK HERE to ADD YOUR VOICE to HepCBC's group submission which will help d
On August 22nd, 2013 the Canadian Agency for Drugs and Technologies in Health (CADTH) released a call for patient input into Janssen Inc.'s new HCV drug, SIMEPREVIR. In order to prepare our Patient Group submission by the Sept. 13th deadline, HepCBC is ASKING for INPUT from HCV+ people and caregivers from throughout Canada, by Wednesday, Sept. 11th. CLICK HERE to ADD YOUR VOICE to HepCBC's group submission which will help determine whether this new treatme